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Abstract
Background: Palliative care has been proposed for progressive non-cancer conditions but there have been few
evaluations of service developments. We analysed recruitment, compliance and follow-up data of a fast track (or
wait list control) randomised controlled trial of a new palliative care service – a design not previously used to
assess palliative care.
Methods/Design: An innovative palliative care service (comprising a consultant in palliative medicine, a clinical
nurse specialist, an administrator and a psychosocial worker) was delivered to people severely affected by multiple
sclerosis (MS), and their carers, in southeast London. Our design followed the MRC Framework for the Evaluation
of Complex Interventions. In phase II we conducted randomised controlled trial, of immediate referral to the
service (fast-track) versus a 12-week wait (standard best practice). Main outcome measures were: compliance
(the extent the trial protocol was adhered to), recruitment (target 50 patients), attrition and missing data rates;
trial outcomes were Palliative Care Outcome Scale and MS Impact Scale.
Results: 69 patients were referred, 52 entered the trial (26 randomised to each arm), 5 refused consent and 12
were excluded from the trial for other reasons, usually illness or urgent needs, achieving our target numbers. 25/
26 fast track and 21/26 standard best practice patients completed the trial, resulting in 217/225 (96%) of possible
interviews completed, 87% of which took place in the patient's home. Main reasons for failure to interview and/
or attrition were death or illness. There were three deaths in the standard best practice group and one in the
fast-track group during the trial. At baseline there were no differences between groups. Missing data for individual
questionnaire items were small (median 0, mean 1–5 items out of 56+ items per interview), not associated with
any patient or carer characteristics or with individual questionnaires, but were associated with interviewer.
Conclusion: This is the first time a fast track (or wait list) randomised trial has been reported in palliative care.
We found it achieved good recruitment and is a feasible method to evaluate palliative care services when patients
are expected to live longer than 3–6 months. Home interviews are needed for a trial of this kind; interviewers
need careful recruitment, training and supervision; and there should be careful separation from the clinical service
of the control patients to prevent accidental contamination.
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Background
Trials of new palliative care services are rare and beset with
serious methodological problems, in some instances so
severe that the studies fail [1]. Systematic reviews have
attempted to assess the effectiveness of palliative home
care [2], multidisciplinary teams [3,4], day care [5], sup-
port for carers [6], services for older people [7] and in
dementia [8]. They identified: (1) a wealth of studies con-
cerned with need rather than treatment, and (2) problems
of trial compliance, recruitment, attrition, contamination,
bias, outcome measurement and definition of the inter-
vention.
This has led some to question whether randomised con-
trolled trials are appropriate in palliative care [1,8]. In
addition, ethical concerns have been raised about ran-
domising patients who may be near the end of life [9].
However, non-randomised and quasi-experimental stud-
ies suffered from similar problems to those found in trials
[4-6]. Robust evaluation and trial methods are urgently
needed. Modelled on clinical trials, with phase I, II and III
studies, the MRC framework for the evaluation of com-
plex interventions has recently provided a useful model
for developing and evaluating services or other complex
treatments [10,11]. The recommendation for palliative
care to expand to encompass non-cancer patients and can-
cer patients earlier in their illness urgently needs evalua-
tion. New methods are required to test services in this
context.
Multiple sclerosis (MS) is one condition where palliative
care is felt to be needed. This chronic disease of the central
nervous system affects over 2.5 million people worldwide
and is the most common cause of neurological disability
in adults under 60 years [12]. As the disease affects many
parts of the central nervous system it may be accompanied
by marked physical and psychosocial symptoms. In a
small proportion of patients the disease may result in pro-
found disability leading to a need for the provision of
complex care and, for some people, information on plan-
ning around end of life care. Although for many the prog-
nosis is good, around 15% of those affected have primary
progressive disease from the outset and a further 35%
develop a progressive course after many years of relapsing
illness. Thus palliative care may have a role for patients
with complex problems, particularly for those with pro-
gressive disease.
We designed and sought to determine whether a new pal-
liative care service for people severely affected by MS
improves their outcomes. However, because poor recruit-
ment, attrition and missing data are commonly high in
palliative care studies [2-4] we wished to test a design not
previously used in palliative care – a fast track (also called
wait list) trial. This analysis aimed to assess the results of
recruitment, compliance, and follow-up of this trial
design in this complex group of patients. The design
sought to minimise missing data for any reason; and
when it was present to understand its patterns and influ-
encing factors. Therefore, we tested the following null
hypotheses: 1) missing data would not be associated with
patient disability; 2) missing data would not be associated
with particular measurement instruments. We explored
whether missing data was associated with any other
patient, outcome or study characteristics, to inform future
imputations. We believe that lessons from our recruit-
ment and trial compliance will add to knowledge in the
field and further the development and application of
appropriate research in palliative care.
Methods
Design, Project Advisory Committee, Ethical (IRB) 
approval
We followed the Medical Research Council (MRC) Frame-
work for the Evaluation of Complex Interventions
[10,11]. This follows a similar framework to that of clini-
cal trials and comprises 5 phases: pre-clinical (theory) and
phases I (service modelling), II (preliminary evaluation of
service), III (full randomised controlled trial), IV (wide
adoption and effectiveness studies). We have previously
reported the pre-clinical and phase I findings, which com-
prised qualitative studies [13-15] and systematic literature
reviews [16]. Here we report phase II – an open ran-
domised controlled trial to test subsequent evaluation
methods and a preliminary comparison of the new service
with standard best practice. Figure 1 uses a graphical
method [17] to depict the interventions, interviews and
timings in the trial.
Although not all phase II MRC Framework studies com-
prise a randomised trial, we wished to do so because: (1)
to begin to operate the service without a trial would make
it very difficult to introduce a trial subsequently, and
might lead to ethical concerns among staff because of an
'apparent' reduction in service, making a phase III trial
impossible, and (2) we felt it important to test the subse-
quent trial methods. However, we chose to conduct a fast-
track versus standard care intervention trial (also called a
wait list trial) because we were concerned about contami-
nation and poor uptake in the control group – a problem
found in many other randomised controlled trials of pal-
liative care services [3,4]. In the fast track (wait list) design
all patients have the possibility to receive the service,
some immediately, and others after a wait (equivalent to
a normal wait for NHS services). The detailed protocol is
presented elsewhere [13] (registered at clinicaltrials.gov,
NCT00364936). A multidisciplinary Project Advisory
Committee (PAC) was established for the duration of the
project. Research ethics committee approval from King'sBMC Palliative Care 2008, 7:7 http://www.biomedcentral.com/1472-684X/7/7
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College Hospital local research ethics committee was
granted for all phases of the project.
Patients and carers
Inclusion criteria were: Patients in South East London
who were living with MS and were deemed (by staff – MS
nurses, neurologists, rehabilitation staff, primary care
staff, social workers – and in a few instances via voluntary
groups and self referrals) – to have specialist palliative
care needs. These referral guidelines were circulated in
advance and explained in an accompanying education
programme and were defined as problems or unresolved
issues with: symptom control, psychosocial needs, end of
life, advanced planning (directive and competency or con-
sent), planning needs for or difficulty with nutrition and/
or hydration or a complex combination of problems. A
consultant in palliative medicine (PE or IJH) not involved
in delivering the service screened all referrals. Patients
were excluded if the referring staff and the screening
deemed they had very urgent needs or were deteriorating
rapidly. In this instance immediate referral to the service
was offered, and the patient was withdrawn from the trial
(required for 5/69 patients). Clinical information was
recorded where possible on those excluded from the eval-
uation to allow further understanding of clinical issues
[13].
Randomisation
Consenting patients were randomised after the baseline
interview to two arms. One arm received input from the
palliative care team immediately (fast track) in addition to
standard best practice services. The other arm was offered
Graphical depiction of intervention in fast track versus standard care trial of a palliative care service Figure 1
Graphical depiction of intervention in fast track versus standard care trial of a palliative care service.
 
Time line  Fast track (immediate 
referral to palliative care 
service) 
Best standard care (wait 
list control) 
 
Consent and Baseline 
Interview 
(a) 
Randomisation   
48 hours   B   
1-6 weeks  C   
6 weeks  (d)  (d) 
6-12 weeks  E   
12 weeks  (f)  (f) 
48 hours after 12 week 
interview 
 G 
12-18 weeks  H  I 
18 weeks    (j) 
19-24 weeks    K 
24-26 weeks  (l)  (l) 
 
(a)  Baseline research interview and consent on entry to the study before 
randomisation 
B  Palliative care assessment within 48 hours 
C  Palliative care team care, including assessment, treatment, referral 
(d)  Research interview at 6 weeks after randomisation 
E  Palliative care team care continues usually ending by 12 weeks, with 
referral on for those patients needing long term care 
(f)  Research interview at 12 weeks after randomisation 
G  Standard care group now offered palliative care team who see person 
within 48 hours of receiving information 
H  Patients now discharged from palliative care team, if have been referred 
on some under care of community team, which continues from this point 
I  Palliative care team now providing care in standard care group, following 
their 12 week wait 
(j)  Research interview at 18 weeks, only for best standard care group, now 
4-6 weeks after they have received the team care 
K  Palliative care team continues to support standard intervention group 
(l)  Final research interview, 24-26 weeks after randomisation BMC Palliative Care 2008, 7:7 http://www.biomedcentral.com/1472-684X/7/7
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the palliative care team only after a > 3 month wait, and
until then received only best practice (standard best prac-
tice) (Figure 1). Statistical colleagues, independent of the
research and clinical team, registered the patients, con-
ducted the randomisation and informed the research
team, who then informed the patients, and if patients
were "fast track" passed their details to the clinical team.
The randomisation used the minimisation method [18]
to give an equal balance between groups of the following:
gender, age, date of diagnosis, and whether patients could
or could not communicate.
Standard best practice
Local services, which were available to all those who
received the new palliative care service immediately and
after a delay, included: MS nurse specialists, district
nurses, social services, general practitioners and hospital
neurology services. A few patients received home physio-
therapy, occupational therapy and/or attended specialist
rehabilitation services or clinics and/or other specialist
involvement, including continence advice, psychiatry
and/or psychology. After 12 weeks of care, patients ran-
domised to this group were offered referral to the pallia-
tive care team, as for the fast track group, as if they had
been on a waiting list. We chose 12 weeks because the
average waiting time for a neurology outpatient appoint-
ment at the time was 12–16 weeks, and because we felt
that the team was likely to demonstrate an effect in this
time. Our pre-clinical and phase I research and advice
from the treating neurologist had suggested that most (if
not all) patients would still be alive at 12 weeks, making
such a wait a realistic option for them.
Fast-track (palliative care team)
This comprised a part-time palliative medicine consultant
(who had received training in both palliative medicine
and neurology), a palliative care nurse (working 3–4 days
per week on average), a psychosocial worker (shared with
the hospital palliative care team, who was on maternity
leave for 7 months during the project), and a service co-
ordinator/administrator. This structure was agreed during
our modelling phase based on patient and caregiver needs
[13-15]. Following referral a team member would aim to
visit a referral to make a comprehensive palliative care
assessment within 48 hours (see Figure 1). Following
assessment by the team, patients who had not seen a neu-
rologist for some time or requiring review by neurologist
were referred to a specialist clinic run by a neurologist
with an interest in MS (ES). MS nurses, neurologists,
social workers and other staff involved in the care of
patients, made referrals. Service met regularly with neurol-
ogists and MS nurses to discuss patients of concern. The
service aimed to complement and not to replace existing
services. Patients were visited in their own homes or in
some instances hospital outpatient clinics, nursing homes
or hospital. After assessment the team suggested ways to
improve management of physical, emotional, social and
other problems, provided specialist welfare benefits
advice and bereavement support, liaised with and acted as
a catalyst with local services, both primary and specialist
teams. Follow-up occurred as required, depending on
clinical need. The service modelling phase, and a pilot
service run by the consultant (RB) suggested that a short
term assessment and care was required, with symptom
control and other actions occurring during 1–3 visits and
then referral on the community palliative care teams if
longer follow-up was needed. The team recorded whether
they assessed patients to have specialist palliative care
needs, as in the referral criteria, and the number of assess-
ments, follow-up and subsequent referrals made.
Research interviews
Face to face interviews were conducted according to a
standardised schedule, using trained interviewers, all with
previous experience interviewing in palliative care. The
interviewers read the questionnaires and outcome meas-
ures to the patients, showing them large cards of the pos-
sible response categories for standard scales. Interviewers
recorded their responses. After the baseline interview,
interviews were repeated for both groups at 6 weeks, 12
weeks, and 24–26 weeks (final interview). In addition, at
18 weeks the standard practice group were interviewed
(aiming to have an interview 6 weeks after receipt of the
palliative care service) (see Figure 1). Because of the high
number of interviews needed at certain times of the study,
and because of staff changes, 10 different interviewers
were used at stages of the project, but one member of staff
conducted the majority of interviews. Questionnaires
were selected following a systematic literature review and
piloting [16], and in addition to the outcome measures
(see below) assessed clinical and demographic circum-
stances and cognitive function (Abbreviated Mental Test
Score, AMTS).
Primary outcome measure
For this analysis our main outcomes were trial compliance
(the extent the trial protocol was adhered to), recruitment
(percentage included in the trial), attrition (percentage
lost to follow-up) and missing data. As our main outcome
point was at 12 weeks (before cross over) we also report
how may interviews were conducted at this point. To
assess patient outcomes we used self-reported question-
naires using the Palliative Care Outcome Scale (POS)
[19,20] and a specially adapted symptom version, POS-
MS symptoms [21] as measured 12 weeks. The former
included 8 items on anxiety, patient and carer concerns,
practical needs and the latter 18 questions specifically
relating to MS symptoms, both using a 0–4 scale.BMC Palliative Care 2008, 7:7 http://www.biomedcentral.com/1472-684X/7/7
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Secondary outcome measures
Self-reported quality of life and impact of MS using the
Multiple Sclerosis Impact Scale (MSIS) [22,23] which
comprises 29 questions (rated 1–5). We also recorded the
patient and caregiver reported use of health and social
services (and experience of hospital services) in order to
calculate the costs of services, to determine whether the
team supplemented or substituted existing services and
together with the outcome data to calculate cost effective-
ness.
In addition, to determine the patients functional status we
used the United Kingdom Neurological Disability Scale –
UNDS [24], which comprises 12 sections to assess disabil-
ity – and using the Expanded Disability Status Scale –
EDSS [25] a single item 10 point interviewer assessed
scale, a the first and final interviews. We recorded the time
taken for the whole interviews.
Carer measures
Carers/families self completed a short separate question-
naire assessing carer burden (using the short form Zarit
Carer Burden Inventory, 12 items each rated 0–4) and
mastery (using the Lawton caregiver mastery scale, 4 items
rated 0–4); either during the patient interview but sepa-
rately, or returned the questionnaire by post.
Amendments to procedures
Two amendments were made (following further ethical
committee approval) early in the study, after reviewing
recruitment of the first 5–6 patients.
(1) Initially patients refusing to enter the trial were offered
the fast track service immediately. This was changed so
that patients refusing the study, and without immediate/
pressing clinical needs, were offered standard best prac-
tice.
(2) We lowered our threshold for including patients with
cognitive and communication difficulties. We always
sought to include all patients where consent and an inter-
view were possible (using technological aids and longer
interviews where appropriate). Initially those with cogni-
tive impairment and severe difficulties communicating
were excluded because of questions about their ability to
provide informed consent. However, as cognitive dysfunc-
tion may be a feature of severe MS, we felt that it was
important to include this group of patients in the evalua-
tion. After discussion with the PAC it was agreed that
patients with severe cognitive impairment were offered
inclusion in the trial, provided their carers/families were
also in agreement. It was felt that being offered a poten-
tially new service that might help them would be in their
best interests and that excluding such patients would
mean excluding some individuals which future palliative
care services might specifically target.
Analysis
In this analysis we determined the response rate, reasons
for acceptance and trial refusal, attrition, follow-up rate
and pattern of missing data and we explored whether
these were related to any patient or study factors. To test
our null hypotheses we tested for correlations between the
amount of missing data and levels of patient disability
using Spearman's rho, and compared the level of missing
data for the different measurement instruments and inter-
viewers using one way ANOVA. In addition, we tested
whether there were differences between randomisation
groups at baseline.
Sample Size
We had estimated that a sample of 25 patients in each arm
would enable us to detect differences of >1.6 on the POS
(for individual items) at p < 0.05, power 80%. The main
time point for analysis of the main trial was 12 weeks.
Large studies have shown that patients with an EDSS of 8
(defined as being unable to walk with limited use of the
upper limbs) or more make up about 15% of the MS pop-
ulation [26]. Based on the local patient numbers of peo-
ple with an EDSS of ≥ 8 we estimated we would identify
3–4 patients per week, and with 60–70% uptake would
recruit and follow up 2 of these. Recruitment over 1 year
would therefore give us 50–52 patients, to give an indica-
tion whether differences between groups were emerging.
Results
Initial recruitment and randomisation
A total of 69 patients were referred to the trial over 11
months. Of these 17 were excluded from the trial. Reasons
for trial exclusion were: deemed to have urgent need
(symptoms and/or deterioration) and so received fast
track service immediately (5); refused consent for the trial
(5); had communication difficulties too severe to include
(3, note 2 of these occurred in the early stages before we
broadened the inclusion criteria); lived outside the visit-
ing area (for service and interviewers) (1); did not have
MS (1); language or cognitive problems (1) and adminis-
trative error (1) when the family member contacted the
team directly, and was mistakenly not offered the trial but
instead received the service immediately.
Of the 5 who refused consent, in one instance this was by
the family and four instances by the patient. Two refusals
(one patient and one family member) were in the early
stages of recruitment before the protocol was amended;
therefore these two patients were offered and accepted the
fast-track service. One family member stated that they did
not want their relative to 'risk waiting three months'
because they 'have had to wait for lots of things'. After theBMC Palliative Care 2008, 7:7 http://www.biomedcentral.com/1472-684X/7/7
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protocol was amended the refusal rate declined. The other
three refusals declined both the study and the service.
The remaining 52 patients were randomised to receive fast
track palliative care (26) or standard best practice (26).
Thus our planned sample size was achieved in one year of
recruitment. Table 1 shows the characteristics of all
patients, those randomised to each arm and excluded
from the study. The characteristics of all groups were sim-
ilar: over 90% were white, the age ranged 33–75 and two
thirds were women. The majority (96%) had either sec-
ondary progressive MS or primary progressive MS. Other
disease types included relapsing remitting MS and similar
inflammatory CNS diseases such as (Neuromyelitis
optica). The mean disease duration was 18 years (SD 9.6
years) before referral to our study; range 0 (a recent diag-
nosis) to 55 years. On average patients had a high degree
of disability, with a mean EDSS score 7.8 (Table 1). Eleven
out of 51 patients had scores of 9 or more meaning that
they were confined to bed. The EDSS and other measures
between the two groups were similar at baseline.
Trial follow-up and attrition
A total of 25/26 fast-track and 21/26 standard best prac-
tice patients completed the trial, see Figure 2. One patient
initially entered the trial but was excluded because of pro-
tocol violation. This patient consented and was ran-
domised to the standard intervention, but due to an
administrative error was seen by the service after only a
baseline interview, rather than at 12 weeks. Because of
limited resources and the preliminary nature of the inves-
tigation the principal investigators (PE and IJH) took the
decision to continue offering the service, but stop further
research data collection, as any such data would have
needed to be analysed separately. The patient was fully
informed about the ending of research interviews. To
ensure that this error did not occur again, subsequently,
when patients were randomised to standard best practice,
details were kept with the research team until after the
third interview at 12 weeks.
Main reasons for loss to follow-up were death or illness.
The causes of three deaths in the standard best practice
group were: myocardial infarction (2), pneumonia com-
plicated by pyogenic pleural effusion with respiratory fail-
ure leading to high dependency admission, complicated
by iatrogenic injury in a patient receiving chemotherapy
(1). The one patient in the fast-track group who died had
spent a great deal of time deteriorating in hospital with
recurrent infections and pressure sores, and was subse-
quently discharged home, as her wish was to die at home.
One further patient in the fast-track group has subse-
quently died, after the end of the study.
By 12 weeks, 26/26 patients had questionnaires returned
in the fast track group and 22/26 (and 23/26 for one ques-
tionnaire) in the standard track group (with some missing
data for individual questionnaire items) (Tables 2 and 3).
As Table 4 shows the interviews occurred at similar time
intervals in fast track and standard groups and at the times
intended (Table 4). At 24–26 weeks, in the fast track
group out of a total possible 104 patient interviews, 102
(98%) were completed – one interview did not occur
because the patient died and one was missed because of
an error in interview timing. In the standard track group
there were 115/130 (88%) completed interviews; eight
were not possible because patients had died, four because
of the protocol violation, and three patients were too
unwell to participate in one interview. Of those patients
who were alive, we completed 217/225 (96%) possible
interviews.
Intervention with team
For the 52 patients included in the trial, team actions
were: 25 patients, one to three visits leading to assessment
that problems were improved and then the patient was
discharged; 21 patients, assessment and communication
with patient and caregiver, general practitioner and refer-
rer and advice other appropriate action or referral (e.g. to
occupational therapy, social services, neurologist etc, note
these patients were all assessed as not having specialist
palliative care needs according to the referral criteria and
so the team felt their main role was to support and refer to
other services); and 6 patients received three assessments
and were deemed as needing long term follow up and
were referral on to community palliative care services. Of
the 17 patients excluded from the trial, 3 refused the trial
and the team and so received no team care, 1 patient was
assessed but did not have MS, 12 received between one
and three visits leading to assessment that problems were
improved and then the patient was discharged and one
patient was cared for and referred on for long-term com-
munity palliative care. All the 13 patients cared for by the
team were assessed as having specialist palliative care
needs, including the 5 'urgent' patients.
Time taken, location and completeness of data collection 
at interview
The mean time to complete the baseline (first) interview
was 91 minutes (SD = 33); subsequent interviews took on
average 61–70 minutes (SD ranged 23–28), and the final
interview averaged 82 minutes (SD = 32), overall range
25–150 minutes. In a very few instances the interviewer
returned on another day to complete the interview. 87%
of interviews occurred in the patient's own home, 6%
were in a nursing home and 2% each in hospital, rehabil-
itation unit, day centre and residential home.BMC Palliative Care 2008, 7:7 http://www.biomedcentral.com/1472-684X/7/7
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Table 1: Characteristics of patients in the two randomised arms and excluded from the study at baseline (n = 69)
Fast Track (FI) (n = 26) Standard Practice (SI) (n = 26) Excluded from study (n = 17)
Gender
Male 9 35% 7 27% 4 24%
Female 17 65% 19 73% 13 76%
Age
Mean 52.9 -- 53.0 -- 53.7 --
Median 53.0 -- 51.5 -- 53.0 --
SD 10.5 -- 10.4 -- 12.2 --
Ethnic Group (grouped)
White (UK, Irish, European) 23 88% 24 92% 13 93%
Any other group 3 12% 2 8% 1 7%
Not known 3
Type of MS
Primary Progressive MS 13 50% 10 38% 5 33%
Secondary Progressive MS 12 46% 14 54% 7 47%
Other (inc Relapsing Remitting and Devics) 1 4% 2 8% 3 20%
Not known 2
Education: continue after min school 
leaving age?
Yes 11 42% 14 54% -- --
No 15 58% 12 46% -- --
Education: degree or equivalent 
qualification?
Yes 9 35% 6 23% -- --
No 17 65% 20 77% -- --
Employment status
Retired 6 23% 5 19% -- --
In employment or self-employed (PT/FT) 0 0% 1 4% -- --
Unable to work (due to illness) 20 77% 20 77% -- --
Did the patient ever work in health or 
social services?
Yes 4 15% 6 23% -- --
No 22 85% 20 77% -- --
Informal carer
No informal carer 6 23% 3 12% 3 23%
Partner (wife/husband) 14 54% 15 58% 7 54%
Offspring (daughter/son) 4 15% 3 12% 1 8%
Sibling (sister/brother) 1 4% 2 8% 0 0%
Parents 1 4% 3 12% 1 8%
All others 0 0% 0 0% 1 8%
Next of Kin
No next of kin 0 0% 1 4% 0 0%
Wife/partner 8 31% 3 12% 3 23%
Husband/partner 7 27% 12 46% 4 31%
Daughter 1 4% 3 12% 1 8%
Son 6 23% 0 0% 2 15%
Brother 1 4% 1 4% 0 0%
Sister 0 0% 1 4% 1 8%
Parents 3 12% 5 19% 1 8%
Any other carer 0 0% 0 0% 1 8%
Not known 4
Type of Carer Contact
Lives alone 5 19% 4 15% 3 25%
Lives with carer 20 77% 21 81% 9 75%
Other carer contact 1 4% 1 4% 0 0%
Not known 5
FUNCTION AND SYMPTOM 
SCALES AT BASELINE
UNDS TOTAL
Mean, (Median) 28.2 (27.5) 29.5 (28.5) -- --
SD 8.9 -- 9.2 -- -- --BMC Palliative Care 2008, 7:7 http://www.biomedcentral.com/1472-684X/7/7
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Missing data items were limited. In the baseline interview
there was a mean of 5.5, median = 0, items missed per
interview (Table 2) out of more than 56 items in the ques-
tionnaire. There was one outlier, a patient who had severe
cognitive problems, and when this individual's data was
excluded the missing data reduced to mean 4.6 items,
median 0 items. Over time (except interview 2) the
amount of missing questionnaire items reduced to almost
none (Table 2). Data for the UNDS and EDSS question-
naire were fully completed, except one interview, apart
from the above patient who could not respond to self-
report questions. There was some missing data for the
MSIS, the POS and the POS-MS. However, this was for
particular interviews/patients rather than for specific
items. In over 85% of interviews, all items were completed
for these questionnaires, and the fast track and standard
groups were broadly similar in terms of missing data
(Table 3).
Surprisingly there was no consistent relationship between
functional disability, measured by EDSS, and missing
questionnaire items, supporting our null hypothesis. Sig-
nificant correlations were not found for interviews at
baseline, I3, I4 or I5, and only a weak correlation between
higher EDSS score (i.e. greater disability) and missing data
for interview 2 (rho= 0.35, p < 0.05). There was, however,
a significant relationship between the amount of missing
data and the interviewer, see Additional file 1. Interviewer
'B' (who conducted 26 interviews) had on average 10–20
more missing data items per interview than all others.
Interviewer 'D' had a slightly higher level of missing data
for the baseline interview; all other interviewers had very
little missing data. Interviewer A, who had a low rate of
missing data, conducted most (137/212, 65%) interviews.
Discussion
We believe that this paper reports the first use in palliative
care of both the MRC Framework and a fast-track control-
led trial. Overall we found our methods successful with
good compliance, endorsing our use of the MRC Frame-
work and this trial design. Further, we achieved our tar-
geted recruitment within the anticipated timescale, had
low attrition (only 5/52 patients) and relatively little
missing data. This is a considerable achievement in this
difficult area but suggests that it can be reproduced.
Because of this patient group, several components of our
methods were costly; we conducted mainly home inter-
views and needed to invest time and resources in the
phase I study, although this helped model the service
[14,15]. In addition, the existing team caring for patients,
including neurologist and MS nurses, were supportive of
investigating the potential of palliative care and thus
referred appropriate patients in sufficient numbers. This
also may have been helped by the phase I study, where
other services were involved in modelling the new inter-
vention. This investment paid off, in resulting in a com-
pleted, to time, phase II study which achieved its target
recruitment.
N completed 26 26
EDSS score
Mean 7.7 (8.0) 7.9 (8.0) -- --
SD 1.0 -- 1.0 -- -- --
N completed 25 26
MSIS Physical score
Mean 67.7 (69.0) 67.0 (70.0) -- --
SD 18.6 -- 10.9 -- -- --
N completed – all items 18 12
MSIS Psychological score
Mean 20.8 (21.0) 24.6 (25.0) -- --
SD 7.5 -- 10.7 -- -- --
N completed – all items 21 17
Core POS total
Mean 14.2 (14.0) 13.3 (14.0) -- --
SD 3.5 -- 4.2 -- -- --
N completed – all items 18 15
POS MSS total score
Mean 18.7 (16.0) 18.4 (18.0) -- --
SD 9.4 -- 10.7 -- -- --
N completed – all items 23 21
Zarit Burden Inventory total
Mean 20.5 (19.0) 22.5 (23.0) -- --
SD 10.7 -- 6.5 -- -- --
N completed – all items 13 17
Note: N = 26 for both FI and SI groups, unless indicated for functional and symptom scales. There were no significant differences between any of 
the groups for any variable, at baseline.
Table 1: Characteristics of patients in the two randomised arms and excluded from the study at baseline (n = 69) (Continued)BMC Palliative Care 2008, 7:7 http://www.biomedcentral.com/1472-684X/7/7
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There are several limitations to this study. We report a
phase II study, designed to test the feasibility of the inter-
vention and the evaluation methods. Many phase II stud-
ies in the MRC framework are more limited than our trial,
often testing the intervention among few patients and not
including a randomised component [27]. In contrast,
phase II drug therapy trials are often randomised. In our
situation, the advantages of a randomised study included
decreasing the effects of patient selection bias and the
ability to ensure that uniform evaluation criteria were
used. Concerned that if the service ran without randomi-
sation, we would never be able to conduct a trial subse-
quently, and unable to find a suitable non-random
comparison group, we appraised the various options for
trial. The fast track randomisation appeared to be most
feasible. However, at this stage, we were unlikely to have
had adequate power for detailed tests comparing the two
groups and the broad referral criteria may have resulted in
some patients being included who were less likely to ben-
efit from the new service. Despite this, the results we
CONSORT DIAGRAM showing flow of patients through the study Figure 2
CONSORT DIAGRAM showing flow of patients through the study.
 
 
 N (N) = patients remaining in study (interviews actually completed at this stage).  
Interviews missed because patient unavailable (away/in hospital) /timing error.   
Patients 
69 
S – I3 
24 
F – I3 
26 
F –final 
25 
S– I4 
22(21) 
Baseline interview 
52 
Excluded / refused 
17 
SI –final 
21 
S– I2 
24(23) 
F – I2 
26(25)  
(1 Protocol violation
1 PwMS died) 
Withdrawn 
2 
 
26 
  
26 
Withdrawn 
1 
(1 PwMS became 
severely ill) 
(2 PwMS died) 
2  Withdrawn 
1 
(1 PwMS died) 
Withdrawn 
Indicates point of 
clinical intervention
Fast track Standard 
   Randomised
Table 2: Amount of missing data for outcome measures in the study, by interview, for patient interviews
Interview and 
type (long or 
shorter)
potential n 
interviews
Total n items/
questions within 
interviews
N patients (%) 
with complete 
data
Total n 
missing 
items
% Missing 
items
Mean (SD) 
missing 
items
Median 
missing 
items
Min Max
Baseline 52 69 28 (54%) 288 8.0% 5.5 (11.6) 0 0 56
I2 48 56 35 (72%) 357 12.8% 7.1 (17.5) 0 0 56
I3 50 56 42 (84%) 103 3.7% 2.1 (9.1) 0 0 56
I4 21(SI only) 56 18 (86%) 92 3.1% 4.4 (15.3) 0 0 56
Final 47 69 20 (95%) 69 4.8% 3.3 (15.1) 0 0 69
Note: There were three outliers – a patient who could not complete questionnaire in any interview, three missed interviews – I2 (2) and I4 (1) 
because of patients being away/in-hospital. These are included in the above analysis. Analysis without these outliers reduces the missing data even 
further, especially the number of missing items as all questionnaire items were missing for these patients. Open response text fields are not 
included as these were for additional comments if individuals wished to make themBMC Palliative Care 2008, 7:7 http://www.biomedcentral.com/1472-684X/7/7
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Table 3: Main outcome measures of the study and data completion by study arm and interview
Questionnaire Multiple Sclerosis Impact Scale 
(MSIS)
Palliative Care Outcome Scale 
(POS)
POS-MS symptoms (POS-MS)
Number of items 29 8 18
Nature of questions Impact of symptoms on day to day life 
in last 2 weeks graded 1 (no problem) 
to 5 (worst problem)
Effect of the problem in the last 3 days 
graded 0 (no problem) to 4 
(overwhelming effect)
Effect of symptom in the last 3 
days graded 0 (no problem) to 4 
(overwhelming effect)
Study arm Fast track Standard Fast track Standard Fast track Standard
Interview 1 (baseline)
Questionnaires returned/
Initial patients entered in 
study arm (%)
25/26 (96%) 24/26 (92%) 25/26 (96%) 21/26 (81%) 26/26 (100%) 24/26 (92%)
Reasons for non 
completion
Patient too disabled to self-
report*
-1- 1- 1
Questionnaire missed at 
interview **
1 1 14- 1
N questionnaires with every 
item completed +
18 12 18 15 23 21
Interview 2 (4–6 weeks)
Questionnaires returned/
Initial patients entered in 
study arm (%)
23/26 (88%) 21/26 (81%) 22/26 (85%) 21/26 (81%) 24/26 (92%) 22/26 (85%)
Reasons for non 
completion
Patient died - 1 - 1 - 1
Patient withdrawn from 
study
-1- 1- 1
Interview missed *** 1 1 1 1 1 1
Patient too disabled to self 
report*
-1- 1- 1
Questionnaire missed in 
interview **
2 1 311 -
N questionnaires with every 
item completed +
19 11 17 20 21 18
Interview 3 (10–12 
weeks)
Questionnaires returned/
Initial patients entered in 
study arm (%)
26/26 (100%) 23/26 (88%) 26/26 (100%) 22/26 (85%) 26/26 (100%) 23/26 (88%)
Reasons for non 
completion
Patient died - 1 - 1 - 1
Patient withdrawn from 
study
-1- 1- 1
Patient too disabled to self-
report*
-1- 1- 1
Questionnaire missed in 
interview **
--- 1- -
N questionnaires with every 
item completed +
26 19 26 19 24 19
* One patient randomized to standard care was too disabled to complete any self-report questionnaire, at any interview
** The completion of some questionnaires were completed missed at interview with no questions being attempted, although the interview took 
place and some other questionnaires were completed.
*** One interview was missed because the patient was not available during the interview period and one was missed because of a timing error.
+ Especially early in the study some single items within questionnaires were not completed. In the MSIS, questions with most missing data were 
'difficulty carrying things' and 'problems using transport'. In the POS, this was 'feeling good about yourself'. Otherwise there was little pattern in 
missing data according to specific items.BMC Palliative Care 2008, 7:7 http://www.biomedcentral.com/1472-684X/7/7
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obtained from this study will allow sample size calcula-
tion in future studies, and have provided valuable infor-
mation on the spectrum of needs of people severely
affected by MS. As this study is likely to be underpowered,
negative or borderline results at this stage should not pre-
vent further development of palliative care for this group
of patients.
Different approaches to conducting trials have developed
in palliative care. These have included cluster randomisa-
tion (where patients in the no service cluster are not aware
they are part of a trial) and studies which offered those
patients in the control group a 'low level' of service
because of fears that patients would not enter the study if
they had no service [28]. Many such trials have suffered
from selection bias and contamination [29]. In a trial of
hospice at home, at the request of the ethics committee
patients were randomised 4 (service) to 1 (control), to
ensure the service was kept full. In addition, patients
referred when the service was 'empty' were offered the
service irrespective of their randomisation. This resulted
in an underpowered control group that appeared to
receive special treatment [30]. All of these studies have
proved problematic, with poor recruitment, attrition and
bias [9,29].
A fast-track randomised trial is often called a 'wait list'
control or delayed intervention trial. They have success-
fully been used to evaluate cognitive behavioural therapy
[31,32], preventive strategies [33], complementary thera-
pies [34] and in rehabilitation [35], neurology and mental
health [36]. However to us, and our PAC (which was
chaired by and included people affected by MS), the term
'wait list' trial seemed inappropriate. In fact, patients were
being offered something much more quickly then they
would usually receive it, and so the term 'fast track' as
compared to "standard care" was adopted. We referred to
the 'standard best practice' group as such, because both
our PAC and the ethical review committee wished to make
it clear to participants that they would receive all services
as best practice currently dictated with no unusual delays
or waits. Such a 'fast track' trial is often not feasible in pal-
liative care, because few control patients would live long
enough to receive the intervention. This is not the case
among patients with longer-term conditions, who are
now being considered for referral to palliative care, and
where much remains to be understood about the effec-
tiveness and cost effectiveness of different models of pal-
liative care. Further, consideration needs to be given to the
length of time the 'standard care' group should wait
before receiving the intervention. As for cross over trials, if
the intervention is expected to produce effects very quickly
then the standard care group might receive the interven-
tion after a shorter wait than in our study. Phase I model-
ling, as in our study, could help to determine this.
We had to make several improvements to our design in
the early stages of the study. Patients with urgent needs
were not randomised (but data recorded) to provide a
whole picture. Patients refusing the trial should be offered
the standard track intervention, not the fast-track, other-
wise the position of equipoise is not maintained and
patients (and/or their carers) are likely to refuse, in the
expectation of receiving the service. This is an important
principal to make clear to staff, and it was only after we
had begun the study that the effects of getting this wrong
became clear to us, and we amended the design. We had
good compliance and uptake for the trial, achieving our
intended numbers and sometimes having more inter-
views to do than one interviewer could manage, probably
because of; a) an uneven distribution of referrals (ranging
up to 6 per week, with an increase after training events)
and, b) slightly different interview schedules in two
groups, with the SI group having one more interview, so
some interviews becoming bunched. Although using the
relatively large number of interviewers allowed us to
examine missing data across interviews, having 10 inter-
viewers in the project may have introduced unreliability,
though we attempted to minimise this with training. It
may not have been ideal for patients and carers, who may
have wished to have the same interviewer throughout the
project. In planning projects in the future resources need
to be put in place for potentially fluctuating numbers of
referrals.
Table 4: Planned and actual times to interview in fast track and standard groups
Time interview planned from baseline Actual time interval from baseline – mean (SD, median) weeks
Fast track Standard
6 weeks 5.54 (1.92, 5) 6.21 (1.71, 5.5)
12 weeks 13.96 (2.93, 13) 12.71 (1.46, 12)
18 weeks (standard only) N/A 18.73 (2.60, 18)
24–26 weeks (final interview) 25.04 (1.09, 25) 26.33 (3.54, 25)
No significant differences between interview times in the two groupsBMC Palliative Care 2008, 7:7 http://www.biomedcentral.com/1472-684X/7/7
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The management of 'urgent' referrals and those with
severe cognitive impairment was another challenge. In
this instance independent consultants in palliative medi-
cine spoke to the referrers and attempted to screen out
cases where need was not acute. However, it may be that
those who were deemed as urgent or very impaired by
referrers were also the group whom palliative care would
benefit most, reducing the chance of finding a difference
in our study. The teams assessment and actions seems to
support this: the team assessed as having specialist pallia-
tive care needs all 13 (excluding refusals or not MS)
patients who were referred directly to the service outside
of the trial, but only 31/52 of those randomised. Although
the clinical team collected outcome data on these urgent
and other referrals, so there is an opportunity to describe
the group, this data is likely to be incomplete and may be
biased. In the future we would advise that these patients
are recruited for data collection by interviewers if possible,
so that their circumstances can be independently verified.
However, this will require additional resources for inter-
views.
Compared to many studies in palliative care [37,38] our
missing data was slight, and considerably less than the
usual levels found in palliative care, where data can be
missing in trials and longitudinal studies for up to 50–
70% of participants [37-42], often because of death or ill-
ness. Cluster randomised trials by Addington-Hall et al
and Jordhøy et al were only able to include less than 65%
of patients at baseline, with rapid attrition even in the first
month [9,37]. We were helped by the careful piloting of
our methods, having a dedicated research team, the initial
service modelling phase (all of which increase the study
costs), and by the fact that people affected by MS have a
much longer illness trajectory than do people with far
advanced cancer. However, we believe we were also
helped by the 'fast track' design, and the knowledge that
all patients would be offered the service, with waits for it
no longer than those for an outpatient appointment. In
our study, recruitment was as expected and only 4 patients
died during the course of the trial. Interestingly, three of
these were in the standard intervention group – although
the causes of death seemed unrelated to the MS.
Another problem in palliative care can be missing data for
individual questionnaire items at interview. In a ran-
domised controlled trial of a home palliative care service,
McWhinney failed to collect enough usable data over time
[43]. In our trial, of those patients who remained alive, we
conducted 96% of all possible interviews, and missed a
median of 0 items, mean 5.5 items out of over 60 per
questionnaire (92% of data items collected). Thus, we had
relatively little missing data and were able to conduct
interviews for around 1 hour with this group, despite a
high level of functional impairment. The amount of miss-
ing data at interview was not correlated with the level of
functional impairment, or the questionnaires used (sup-
porting, to our surprise, our null hypothesis). However,
missing data was related to the interviewer. Many of our
people with MS were very disabled, making interviews
sometimes more difficult to conduct and potentially dis-
tressing for interviewers. This suggests that continued
training, careful supervision and monitoring are needed,
with feedback to and support of interviewers at an early
stage. It also suggests that although we had little missing
data, we might have been able to reduce this even further.
It indicates that highly skilled quantitative interviewers
are needed in palliative care research, because they have to
deal with sensitive issues while collecting data within
standard questionnaires, often not an easy task. There is
often an emphasis on the experience and interviewing
skills of qualitative researchers, but some funding agen-
cies suggest that quantitative interviews need not be so
experienced. However, our study suggests that skilled and
well-trained quantitative interviewers are also important
for the quality of research data. This has important impli-
cations in some countries: for example in the UK there is
a belief that central National Cancer Research Institute
nurses, who are involved in a range of cancer studies,
could be an interviewing resource for palliative care stud-
ies. Our study suggests that careful training and assess-
ment would be needed to establish if this were the case.
Conclusion and Recommendations
Our experience suggests that the use of fast track ran-
domised controlled trial (sometimes called a wait list
trial) used within the context of the MRC Framework, is
feasible and successful in palliative care, when patients
have a longer prognosis and are likely to be alive to receive
the service after the 'wait' period. We propose that this
trial methodology could be used to evaluate new pallia-
tive services in cancer or non-cancer patients who have
similar illness trajectories. This might apply to other neu-
rological conditions, e.g. Parkinson's disease, and some
organ failures, e.g. COPD, and supportive, primary or ear-
lier stage palliative cancer care. Good collaboration with
referring services, in identifying appropriate patients is
essential. For those with urgent needs data should be
obtained and analysed separately. Our method and expe-
rience provides a template for future studies in palliative
and supportive care. We also found that missing data is
mainly interviewer dependent, requiring careful supervi-
sion systems. The standard questionnaires used in this
study – MSIS, POS, UNDS – appear to work functionally
well and have little missing data in this population. Figure
3 shows our main recommendations for those developing
and evaluating new palliative care services (especially for
patients expected to have longer trajectories). If followed
these should significantly improve the quality of palliative
care trials, and take advantage of the major opportunityBMC Palliative Care 2008, 7:7 http://www.biomedcentral.com/1472-684X/7/7
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that currently presents itself to conduct trials among non-
cancer patients. There is also a need to educate funders of
services and research to provide sufficient resources to
conduct evaluation of services in this way.
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Recommendations for those developing new palliative care services, especially for those patients with longer 
trajectories.
 
 
1.  Use mixed methods to establish local need, consult with user groups and 
professionals, and to model the service, and pilot measures; 
2.  Consider a fast track design, where those refusing the trial receive the control arm as 
default; 
3.  Train staff within the service, and researchers/interviewers in the need for the trial, 
data collection tools, interviewing;  
4.  Publicise the service widely throughout the operation, with local training to raise 
awareness and prompt referral; 
5.  Agree referral criteria and definitions of “Urgent” and review appropriateness of 
referrals during trial.  
6.  Separate the clinical team and staff delivering the intervention from any possible 
contact with the control arm, or possible access to their records.   
7.  Employ sufficient interviewers to be able to manage a sudden influx of referrals and 
train, supervise and monitor these carefully; 
8.  Use experienced independent consultants in palliative medicine to screen referrals; 
9.  Be cautious about allowing suggested ‘urgent’ referrals to directly receive the service 
outside of the trial, and when this attempt to recruit them and collect data 
10. Conduct home interviews, and allow for travel time; if necessary with a break 
11. Develop effective systems to monitor interviews and missing data carefully, and 
intervene early if this is apparent; 
12. Work in close collaboration with user groups and other clinical experts – e.g. in our 
case with neurology and rehabilitation staff. 
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